TMO:NYSEThermo Fisher Scientific Inc Analysis

Thermo Fisher Scientific is trading at $509.81, which sits just below its 20‑day SMA of $515.83 and its 200‑day SMA of $511.47, while the 14‑day RSI of 38 suggests the stock is edging toward oversold territory. The MACD line has crossed above its signal line, generating a bullish histogram (+2.22) that hints at a short‑term price rebound, though volume has been trending down and 30‑day volatility remains elevated at 26%. Valuation metrics show a trailing P/E of 28.8, higher than the industry average of 25.4, yet the forward P/E compresses to 19, reflecting strong earnings growth expectations (forward EPS $26.89 vs trailing $17.72). The DCF‑derived fair value of $139 is far below the market price, flagging the stock as potentially overvalued, but analyst consensus projects a 30% upside with a median target of $667, supporting a growth‑oriented case.
Fundamentally, TMO delivered 7.2% revenue growth to $44.6 B, with solid profitability (operating margin 21%, net margin 15%) and robust cash generation (free cash flow $4.39 B). The dividend yield of 0.35% and a modest payout ratio of 9.7% indicate dividend sustainability. Recent news highlights a robust earnings beat, new product launches—including a Cryo‑EM drug discovery center and rapid Candida detection media—and continued strategic investments, all of which reinforce its market leadership. However, the company carries a high debt‑to‑equity ratio of 77, which investors should monitor alongside a neutral sector outlook.